Forbion Capital Partners
|
Forbion Capital Partners Employees in Amsterdam: 12 |
Company Profile
The Forbion team is specialized in the evaluation of late stage preclinical / early stage clinical development programs. We focus on companies that have innovative technologies and drug development programs with unique advantages over current treatments. Furthermore, we invest in biomedical technologies with a focus on interventional cardiology.
Our involvement continues beyond the initial investment. We work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of our portfolio company's technologies.
The Forbion team began operating in 2000 as ABN AMRO Capital Life Sciences, the Venture arm of ABN AMRO Bank NV. In December 2006 the group broadened its investor base, became independent, and changed its name to Forbion Capital Partners. Throughout this time the Forbion team has successfully divested from a series of companies, and currently has EUR 200 million under management.
Keywords
- Venture capital
- Biotech start-up
- Financing
